National Academies Press: OpenBook

The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions (2013)

Chapter: Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors

« Previous: Appendix F.2: Russian Research Personnel and Funding
Suggested Citation:"Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×

Appendix F.3

Russia’s Pharmaceutical and Biotechnolgy Sectors

1. PLAN FOR PHARMA 2020

The plan was set forth by Prime Minister Vladimir Putin, February 2008, to provide a basis for developing the pharmaceutical industry. However, funding began only in 2010. Given the uncertainties in moving forward, the timetable is widely recognized as being overly optimistic; and some anticipated outcomes may not materialize, even after delays. But the program was codified in a government decree in April 2012, and implementation efforts are under way. (Decree of the Chairman of the Government of the Russian Federation, April 24, 2012, No. 1853P-P8, Complex Program for Development of Biotechnology in the Russian Federation from Now until 2020)

Objectives by 2020:

•   Russian producers’ share of domestic market: 50 percent.

•   Innovative products in domestic market: 50 percent.

•   Average value per product: $40 million.

•   Number of innovative molecules: 200.

•   Full-cycle production of products within category of “national security”: 400.

Milestones:

•   By 2012: Import substitution of generics.

•   By 2014: 40 licenses for domestic manufacture of Russian products.

Suggested Citation:"Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×

•   By 2019: Import substitution for 140 drugs and vaccines.

•   By 2020: Domestic innovations for 20 exports.

Achieving domestic innovations for export (2016–2020):

•   Financing: Grants, venture financing, industry financing. Initial state investment of $1 billion, and eventually industry investment of $1 billion.

•   Drugs based on postgenomic period achievements.

•   Research centers for drug design.

•   New generation of research specialists, together with consultations with foreign scientists.

2. INTERESTS OF RUSSIAN BIOTECHNOLOGY SOCIETY AND BIOINDUSTRY ASSOCIATION

A. Regional Biotechnology Programs: Tatarstan Republic, Chuvash Republic, Kirov Oblast, Penza Oblast, Karelia Republic, Tomsk Oblast, Novosibirsk Oblast, Kaliningrad Oblast, Belgorod Oblast, Voronezh Oblast.

B. Enhancement of Business Structures: Microgen production of vaccines. Rosagrobioprom production of animal drugs. Bioprocess Group production of genetically engineered products. Biotechnology Corporation development of biofuels. Biochem Zavod development and production of animal feed proteins and biofuels.

C. Other Initiatives:

•   State program of “Biotechnology Development” (BIO 2020).

•   Technology platforms: “Medicine of the Future,” “Bioindustry and Bioresources,” “Bioenergy.”

•   Ten new investment projects.

•   Skolkovo and Rusnano megaprojects.

•   New venture funds.

•   Target program of Russian Academy of Sciences, “Fundamental Science for Medicine.”

•   Increased funding for Federal Target Programs and for Russian Fund for Basic Research.

•   Outreach through new journals, Web sites, and conferences.

•   Increased educational opportunities for young scientists.

SOURCE: Representatives of Russian Biotechnology Society and Bioindustry Association, September 2011.

Suggested Citation:"Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×

3. EXAMPLES OF INVESTMENTS BY COMPANIES REGISTERED IN RUSSIA

•   Russian-led joint venture SynBio is a $105 million public-private partnership. Rusnano invested $42 million, and the remainder was by Russian-owned HSCI, Russian-owned Pharmasynthez, U.K.-owned Lipoxen, and German-owned SymbioTec. The owners invested cash, stock, and intellectual property. First products include (a) drugs based on Histone H1 for cancer and other diseases, and (b) Poplyxen for biobetters aimed at diabetes mellitus, Alzheimer disease, chronic kidney disease, and cardiovascular disorders.

•   BIND Biosciences, with an investment by Rusnano of $25 million, is to develop new therapeutics against cancer, inflammatory diseases, and cardiovascular disorders. Rusnano has also invested $25 million in Selecta Biosciences, which is developing synthetically engineered vaccines for smoking cessation, type 1 diabetes, cancer, and allergies. Both companies were cofounded by professors at Harvard Medical School.

•   Another Rusnano-funded company at $4.5 million, BiOptix Diagnostics, is a maker of label-free biodetectors.

•   Also, Rusnano invested $26 million in Panacela Labs, a subsidiary of Cleveland BioLabs.

SOURCE: www.genengnews.com/keywordsandtools/print/3/25235/; accessed March 10, 2012.

4. EXAMPLES OF OTHER INVESTMENTS BY INTERNATIONAL COMPANIES

•   Viiv, a venture of GlaxoSmithKline and Pfizer, agreed to supply bulk products, technology, and expertise to the Russian firm Binnopharm, which will carry out secondary manufacturing and packaging of drugs for HIV treatments.

•   Roche granted TeaRx development and commercialization rights for treatment of patients in Russia at risk of thrombosis. TeaRx is scheduled to launch clinical studies in 2012 in Russia. TeaRx may add additional drugs to its portfolio.

•   ChemRar and Pfizer have announced a collaboration focused on drugs and vaccines for cardiometabolic infection and oncological diseases.

•   Johnson and Johnson signed a Memorandum of Understanding with ChemRar in June 2012 to launch a number of initiatives within the next 5 years for the treatment of tuberculosis, cancer, and hepatitis C.

Suggested Citation:"Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×

5. DEVELOPMENT OF RUSSIAN BIOTECHNOLOGY PLATFORMS FOR NEW PRODUCT DEVELOPMENT

•   Platform participants assessing inputs from state representatives and experts in a wide array of fields, including:

images   Forest biotechnology

images   Food biotechnology

images   Aquaculture biotechnology

images   Industrial biotechnology

images   Agricultural biotechnology

images   Ecobiotechnology

•   Participating institutes include:

images   Siberian State Medical University

images   Lomonosov Moscow State University

images   Russian Technologies State Corporation

images   Kurchatov Institute for Atomic Energy

•   Specific priority areas for the near future include:

images   Biorefineries

images   Platform chemicals

images   Bioplastics and biomaterials

images   Biocatalysis

images   Transgenic plants and animals

images   Valorization of waste

images   Pulp and paper

images   Functional foods and feeds

SOURCE: Russian Biotechnology Association, September 2011. Updated during subsequent discussions in Moscow.

Suggested Citation:"Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×
Page 229
Suggested Citation:"Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×
Page 230
Suggested Citation:"Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×
Page 231
Suggested Citation:"Appendix F.3: Russia's Pharmaceutical and Biotechnology Sectors." National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. doi: 10.17226/18277.
×
Page 232
Next: Appendix F.4: Assessment of Developments in Agrobiotechnology in the United States and Russia »
The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions Get This Book
×
Buy Paperback | $54.00 Buy Ebook | $43.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

In the fall of 2010, the U.S. National Academies (consisting of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine) and the Russian Academy of Sciences (in cooperation with the Russian Academy of Medical Sciences and the Russian Academy of Agricultural Sciences) initiated a joint study of U.S.-Russian bilateral engagement in the biological sciences and biotechnology (hereinafter collectively referred to as bioengagement). The U.S. Department of State and the Russian Academy of Sciences provided support for the study. The academies established a joint committee of 12 leading scientists from the two countries to assess bioengagement activities since 1996 and to provide recommendations as to collaborative efforts in the near future. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions summarizes the principal conclusions and recommendations of the study.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!